Mwyngil Takes Non-GLP-1 Route to Obesity Drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mwyngil Therapeutics is developing weight loss treatments that deliberately avoid targeting the GLP-1 receptor, setting itself apart from most obesity drug startups.
- CEO Luba Greenwood, a biotech veteran, told STAT the non-GLP-1 angle was what attracted her to the company, saying she was "not interested in another 'me too' GLP-1" candidate.
- The GLP-1 drug class has surged into mainstream awareness over the past few years, appearing on billboards, in TV ads, and across magazine coverage.
- Most startups entering the multibillion-dollar weight loss market are pursuing their own GLP-1-based drug candidates, making Mwyngil's approach a contrarian bet.
- Greenwood's remarks to STAT marked her first interview about Mwyngil, which is pronounced "mwin-gull."
Why it matters: Mwyngil is wagering that the obesity drug space, currently dominated by GLP-1 candidates from Novo Nordisk, Eli Lilly, and a wave of imitators, will reward genuinely differentiated mechanisms over incremental copies — a bet that, if validated, could open a parallel track for non-GLP-1 obesity therapeutics.
